-
ALSO READ
Cadila hits 52-week low on 14 observations from USFDA for Moraiya plant
Regulatory issues bridle pharma returns, USFDA scrutiny a major hurdle
Zydus Pharma gets USFDA nod to market attention-deficit hyperactivity drug
Zydus Cadila's US arm Nesher Pharma gets 11 observations from USFDA
What's bugging Indian, Chinese medicine companies making crucial heart drug
-
Drug firm Cadila Healthcare on Thursday said it has received approval from the USFDA for Haloperidol Decanoate injection used in treatment of schizophrenia.
The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, Cadila Healthcare said in a BSE filing.
Haloperidol is used in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette syndrome.
RECOMMENDED FOR YOU